The pathogenesis of persistent HIV-associated inflammation during long-term antiretroviral therapy Steven G. Deeks Professor of Medicine University of.

Slides:



Advertisements
Similar presentations
Impact of Tryptophan Catabolism on CD4+ T Cell Recovery and Mortality in HIV-infected Ugandans Initiating ART Peter W. Hunt, Sheri Weiser, Yong Huang,
Advertisements

Evaluation of Human Thymic Function during Health and HIV-1 Infection
New concepts in HIV: HIV immunopathogenesis, treatment and vaccine strategies - report back from pre-conference Nicolas Chomont VGTI-Florida.
Immune Activation/Inflammation and HIV Disease Prof. Georg Behrens Department for Clinical Immunology and Rheumatology Hannover Medical School Germany.
Evaluating residual HIV reservoirs Background or why is this important? What can be measured? Where should we measure it? Conclusions.
Interventions to Reduce Inflammation and Immune Activation in Treated HIV Infection Peter W. Hunt, MD Assistant Professor of Medicine UCSF HIV/AIDS Division.
Immuno-virological discordance in treated suppressed patients Julià Blanco IGTP/IrsiCaixa Badalona, Catalonia, Spain.
HLA-B57 does not fully explain the ability of HIV controllers to clear HCV infection Alice K. Asher 1, RN, MS; Glenn-Milo Santos 1, MPH; Jennifer Evans,
Should we treat HIV Controllers ? IAS 2013 Pr Olivier Lambotte Department of internal medicine and clinical immunology Bicêtre Hospital, University Paris.
The role of HIV infection and Co-infections in Serious Non-AIDS Events Peter W. Hunt, M.D Associate Professor of Medicine, UCSF.
Controversies in HIV Cure Research Debate 1. Is there ongoing replication under HAART? Mario Stevenson and Frank Maldarelli Moderator: Steve Deeks.
Why may non-communicable diseases occur more often in those with HIV infection? Suzanne Crowe Co-Head Centre for Virology, Burnet Institute Consultant.
Slide 1 of 11 From CB Hicks, MD, at Chicago, IL: May 20, 2013, IAS-USA. IAS–USA Charles B. Hicks, MD Professor of Medicine Duke University Medical Center.
Immunopathogenesis of AIDS, an historical perspective: Or 30 years in 15 minutes Michael M. Lederman, MD.
Why is inflammation elevated in treated HIV infection and why does it matter? Steven G. Deeks Professor of Medicine University of California, San Francisco.
Marian Kerbleski, RN UCSF AIDS Division San Francisco General Hospital.
Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,
2014 “Towards an HIV Cure” symposium Melbourne The Immune Checkpoints PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify.
Slide 1 of 24 From DC Douek, MD, at San Francisco, CA: March 24, 2013, IAS-USA. IAS–USA Daniel C. Douek, MD, PhD Bethesda, Maryland Immune Activation,
Cardiovascular Disease: Predicting Risk and Monitoring Outcomes Monica R. Shah, MD, FACC NHLBI AIDS Coordinator Conference on Retroviruses and Opportunistic.
Role of Adaptive vs. Innate Immune Activation in non-AIDS Morbidity Peter W. Hunt, MD Associate Professor of Medicine UCSF HIV/AIDS Division.
Long Term Management of HIV Infection in Aging Adults: Current Challenges, Future Strategies Andrew Zolopa, MD Stanford University.
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
Toronto I-II 4:00 pm The end of AIDS: HIV as a chronic inflammatory disease Steven Deeks Professor of medicine in residence at the University of California,
HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3,
Slide 1 of 10 From DC Douek, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IAS–USA Daniel C. Douek, MD, PhD Bethesda, Maryland Immune Activation, HIV Persistence,
Diastolic Dysfunction is Common in Asymptomatic HIV Patients Priscilla Y. Hsue 1,2, Husam H. Farah 1,2, Ann F. Bolger 1,2, Swapna Palav 2, Samira Ahmed.
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
Background Acknowledgements: Support was provided by NIAID grants U01 AI042170, U01 AI and U01 AI (CPCRA & INSIGHT) and R44AI (NIAID.
HIV/renal studies (CHIC) Baseline renal function as predictor of HIV/renal disease progression –Death, opportunistic infection –Severe chronic kidney disease.
Characterization of persistent HIV-1 in a broad spectrum of CD4 + T-cells isolated from peripheral blood, bone marrow, lymphoid tissue and gut associated.
Impact of Highly Active Antiretroviral Therapy on the Incidence of HIV- encephalopathy among perinatally- infected children and adolescents. Kunjal Patel,
T-Cell Senescence & Inflammation HIV Research Catalyst Forum, April
Mirko Paiardini, PhD Emory University, YNPRC
Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,
Peter W. Hunt, MD Associate Professor of Medicine in Residence
HIV Infection and Accelerated Aging Why is this happening? What can be done to prevent or reverse the process? Steven G. Deeks, MD Professor of Medicine.
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
Factors Associated with Survival in HIV-Infected African Patients on Antiretroviral Therapy: The Impact of a Sampling-Based Approach to Address Losses.
The role of treatment versus disease in causing premature non-AIDS morbidity Judith S. Currier, MD University of California, Los Angeles.
Learning About an HIV Cure by Doing Studies in HIV+ Subjects Alan Landay, PhD Professor and Chairman Department of Immunology/Microbiology Rush University.
What drives persistent immune activation/inflammation in cART-treated HIV-1? Giulia Marchetti, MD, PhD Dept of Health Sciences, Clinic of Infectious Diseases.
Supported by: NIAID/NHLBI R24 AI067039, NIAID R21 AI Viremia copy-years: A measure of cumulative HIV burden among patients initiating antiretroviral.
Evidence for the link between markers of inflammation, coagulation and immune activation and end organ disease Session: Immune Activation/Inflammation.
Persistent immune activation despite suppressive HAART is associated with higher risk for viral blips in HIV-1 infected individuals Alexander Zoufaly 1.
HIV pathogenesis The course of HIV infection 1. Acute Phase 2. Intermediate (asymptomatic) phase -viral load stabilizes at a “set point”. 3. Late (symptomatic)
HIV: Science, Sex and Society. Lecture 1. Mechanisms of viral persistence in the face of antiviral therapy. Mario Stevenson, Ph.D Department of Medicine.
Clinic-based Translational Research Cohort/ Clinical Trial Immunology Core Lab (Sinclair) Basic Immunology Lab (McCune) Virology Core Lab (Liegler) Basic.
Can early antiretroviral therapy fully restore health? Workshop on Pathogeneses and Management of Long-Term Complications of ART IAS Conference, Rome July.
Immune reconstitution Anjie Zhen, PhD
Conclusions Materials and Methods Background Objectives HIV-1 RNA is the most significant determinant of cervical HIV-1 shedding. Shedding has also been.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
Slide 1 of 44 From SG Weibel, MD, at San Francisco, CA: May 6, 2016, IAS-USA. Getting Hotter As We Get Older Sara Gianella Weibel, MD Assistant Professor.
HIV ‐ 1 replication activates CD4 + T cells with specificities for persistent herpes viruses by Anna Haas, Manuela Rehr, Frederik Graw, Peter Rusert, Walter.
Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Antiretroviral Therapy on Viral Load, CD4.
Pathophysiology of Non-Communicable Diseases in Treated HIV Infection: Is there a common path? Peter W. Hunt, MD Associate Professor of Medicine Division.
Alexander Pasternak Laboratory of Experimental Virology, Department of Medical Microbiology Academic Medical Center of the University of Amsterdam Amsterdam,
Immune Ageing and Viral Co-Factors
The impact of treatment duration on defective and expanded identical HIV genomes in T cell subsets from peripheral blood and tissues Eunok Lee.
Chronic immune activation in HIV associated Non Hodgkin lymphoma and the effect of antiretroviral therapy Brian Flepisi University of the Western Cape.
Coinfection With HIV-1 and HCV—A One-Two Punch
Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load by Steven G. Deeks, Christina.
The Impact of Aging on People Living with HIV
Steven G. Deeks, Russell Tracy, Daniel C. Douek  Immunity 
Residual Disease and Immune Activation/Inflammation on ART
Volume 141, Issue 4, Pages e3 (October 2011)
Coinfection With HIV-1 and HCV—A One-Two Punch
Steven Yukl UCSF and San Francisco VA
Steven G. Deeks, Russell Tracy, Daniel C. Douek  Immunity 
Effect of Hepatitis C Eradication on Markers of Macrophage Activation and Microbial Translocation in HIV Seropositive Women Kerianne Burke1, Elizabeth.
Presentation transcript:

The pathogenesis of persistent HIV-associated inflammation during long-term antiretroviral therapy Steven G. Deeks Professor of Medicine University of California, San Francisco

Untreated and to a lesser degree treated HIV infection is associated with increased frequency of “activated” (CD38+ HLA-DR+) T cells 2

Activated CD38+ HLA-DR+ T cells are rapidly turning over in untreated disease Srinivasula et al., Blood 2011

Pre-treatment activation “set-point” strongly predicts extent of activation during suppressive HAARART Hunt et al, CROI 2010, Poster #306, and submitted

UARTO: High CD8+ T aell activation at month 6 of HAART predicts mortality in Ugandans with VL<400 In Cox Proportional Hazards models, each 10% increase in the frequency of activated (%CD38+ HLA-DR+) CD8+ T cells was associated with an increased hazard of death even after adjustment for baseline CD4 count (HR: 1.62, P=0.048) or month 6 CD4 count (HR: 1.61, P=0.042). Hunt et al, CROI 2010, Poster #306, and submitted

Why are “activated” T cells elevated in antiretroviral-treated disease? Residual HIV replication CMV (and other prevalent co-infections) Microbial translocation Lack of immunoregutory responses Thymic dysfunction and residual defects in adaptive immune responses Lymphoid fibrosis Co-morbid conditions (metabolic syndrome, central adiposity)

Does residual replication during HAART contribute to chronic inflammation? 7

Raltegravir intensification had no effect on CD8+ T cell activation (blood and GALT) suggesting that active viral replication is not a causes of persistent inflammation 30 20 % CD38+HLA-DR+ CD8+ T cells (blood) 10 PBO RGV 4 8 12 16 20 24 Weeks Hatano et al., JID 11

Massanella et al., CROI 2011

The size of HIV reservoir (as defined by RNA/DNA ratio) is associated with frequency of activated CD4+ T cells in rectal tissues The GALT RNA was quantified from the LTR (long/processive transcripts), and thus represents a sum of unspliced and spliced HIV RNA. Based on the PLUS study, very little of this RNA should be spliced. Hatano, Hunt, Yukl and Wong (IAS 2011)

Microbial translocation 11

Most (but not all) studies have shown that HIV infection results in mucosal damage, microbial translocation and inflammation; this effect persists during HAART Brenchley JM Nature Medicine 2006

Levels of sCD14 (a marker of LPS and/or monocyte/macrophage activation) predicts mortality in HIV disease independent of other factors (SMART study) Sandler JID 2011

Chronic CMV Infection 14

CMV elicits massive immune responses even in asymptomatic young HIV uninfected adults Sylwester/Picker, JEM, 2005

CMV-specific T cell responses are approximately five fold higher in treated HIV infected adults Naeger et al, PLoS ONE 2009

Higher CMV-specific CD8 IFN-γ production associated with atherosclerosis in several studies Hsue et al, AIDS, 2006

Loss of T cell regenerative capacity and altered immunoregulatory responses 18

HIV-associated inflammation → T reg response → TGF-β → Collagen deposition → Fibrosis → Reduced IL-7 → Reduced T cell regeneration → Inflammation CD3+ Collagen 1 + Desmin +

T Cell Proliferative Defect Inflammation increases IDO production which in turn causes Th17 depletion, microbial translocation and more inflammation T Cell Proliferative Defect ↓Tryptophan IDO Induction in DC/MØ IFN-γ LPS ↑HAA Th17 Depletion Microbial Translocation Favre/McCune Science Translationa Med 2010 Hunt et al, IAS, 2011, #MOAA0105

Telomeres and Telomerase 21

Telomerase (a reverse transcriptase) is inhibited by certain NRTIs (ZDV, d4T, TDF), and treated HIV disease is associated with shorter telomeres Strahl and Blackburn. Nuc Acid Res 1994:22:893–900 Leeansyah et al. 6th IAS on Pathogenesis, Clinical Research and Prevention, Rome, July 2011; Poster TUPE127

Annu Rev Med 2011;62:141-55.

Conclusions T cell activation as defined by CD38 and HLA-DR expression remains elevated during HAART Functional characteristics of cells not fully defined T cell activation associated with disease Multiple mechanisms cause activation during HAART Residual HIV replication (controversial) Microbial translocation (controversial) CMV and other co-pathogens (needs confirmation) Loss of T regulatory cells and other immunoregulatory responses Lymphoid fibrosis (may be central to preceding causes) Homeostatic proliferation (not “activation”) Telomerase inhibition (indirect effect) Metabolic syndrome, abdominal obesity

NIAID RO1 AI087145, K24AI069994, CNICS (5R24AI067039), CLIC Acknowledgements SCOPE Cohort / UCSF Peter Hunt Hiroyu Hatano Jeff Martin David Naeger Rebecca Hoh Rick Hecht Vivek Jain Elizabeth Sinclair Lorrie Epling Mike McCune Elsewhere Netanya Sander Danny Douek Michael Lederman Alan Landay Russell Tracy April Ferre Barbara Shacklett Tim Shacker Ashley Haase Larry Corey Robert Kaplan Sharon Lewin NIAID RO1 AI087145, K24AI069994, CNICS (5R24AI067039), CLIC